Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 97,116

Document Document Title
WO/2014/052659A1
The present invention includes crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide disulfate and crystalline forms of 2-amino-3-methyl-N-(2-morpholinoethyl)-pentanamide monosulfate. Furthermore, the present invention ...  
WO/2014/048071A1
The present invention relates to a pharmaceutical composition of PRCP antagonist, PREP antagonist, or PRCP-PREP dual antagonist. The present invention also relates to a pharmaceutical composition jointly using PRCP antagonist and mTOR an...  
WO/2014/046391A1
The present invention relates to a pharmaceutical composition for treating or preventing protein tyrosine phosphatase sigma (PTPσ)-mediated diseases, and provides a pharmaceutical composition for treating or preventing PTPσ-mediate dis...  
WO/2014/046544A1
The present invention relates to compounds compound according to Formula (1): and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have serotonin (5-HT) transporter inhibitory effects and 5-HT 2C receptor...  
WO/2014/046247A1
 Provided is a method for adjusting the balance of TNF-R1 and TNF-R2 in cells present at a target organ, tissue or site. In the adjustment method provided by the present invention, (1) if raising the abundance of TNF-R2 present in a ta...  
WO/2014/045156A1
Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, met...  
WO/2014/045031A1
This invention relates to compounds (Formula (1)) that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing...  
WO/2014/044790A1
The present invention relates to a DYRK1A inhibitor or an inhibitor of DYRK1A gene expression for use in the treatment or prevention of hypothyroidism in a Down Syndrome patient.  
WO/2014/047116A1
Provided herein is technology relating to liposomes and particularly, but not exclusively, to compositions of liposomes encapsulating a biologically active agent, methods of preparing liposomes encapsulating a biologically active agent, ...  
WO/2014/045162A1
Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I, as defined in the specification. Corresponding pharmaceutical compositions, methods of trea...  
WO/2014/047323A1
Embodiments of the invention generally relate to methods and supplements for treating post-traumatic stress disorder in human beings. Other embodiments of the invention generally relate to methods and supplements for improving sleep effi...  
WO/2014/044721A1
The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine, INN: vortioxetine), having an XRPD pattern with cha...  
WO/2014/047153A1
The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition...  
WO/2014/046472A1
The present invention provides a rivastigmine medicine having improved stability. The invention also provides a method, for packing pharmaceutical medicines containing rivastigmine, capable of improving stability.  
WO/2014/041007A1
The present invention relates to compounds of formula (I) wherein R1 is phenyl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkoxy, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy...  
WO/2014/040969A1
The present invention is concerned with 2-oxo-2,3-dihydro-indoles of general formula (I) wherein (N1) is phenyl or a heteroaryl group, selected from pyridinyl, pyrimidinyl, imidazolyl, isoxazolyl or pyrazolyl; (N2) is phenyl or pyridinyl...  
WO/2014/041106A1
The invention relates to compounds of formula (I), wherein R1 is phenyl or pyridinyl, optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen and lower alkoxy substituted by halogen; X1 is -N= or ...  
WO/2014/041111A1
Inhibitors of USP30 and methods of using inhibitors of USP30 are provided. In some embodiments, methods of treating conditions involving mitochondrial defects are provided.  
WO/2014/041179A1
A method of treating or preventing peripheral neuropathy in a subject determined to be in need thereof comprising: topically administering to the subject an anti-peripheral neuropathic compound acting as GFRα3 type receptor agonist.  
WO/2014/040228A1
The present invention relates to the stabilised amorphous form of the compound of formula (I), to a process for its preparation and also to pharmaceutical compositions or medicaments containing it.  
WO/2014/043110A3
The invention provides powerful methods and compositions for designing, selecting, fine-tuning and optimizing polymer nanogel and other supramolecular assemblies for various properties including, for example, particle size, density and m...  
WO/2014/043685A1
Disclosed are compositions, such as liquid and solid nutritional compositions, that contain beta-hydroxy-beta-methylbutyric acid and optionally at least one protein, carbohydrate, fat, or a combination of protein, carbohydrate, and fat. ...  
WO/2014/043330A1
Disclosed are methods of modulating and/or decreasing serum corticosterone levels in an individual affected by stress. Further disclosed are methods of modulating the hypothalamic pituitary adrenal response in an individual. The methods ...  
WO/2014/042238A1
The invention provides a novel sulfonamide compound useful as a drug having a TRPM8-blocking effect. Specifically, the invention provides a sulfonamide compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (I...  
WO/2014/042176A1
Provided are an industrially useful method for producing a fused-heterocyclic derivative or salt thereof which is useful as a preventive agent, therapeutic agent, reproductive adjustment agent, contraceptive, ovulation-inducing agent, or...  
WO/2014/041175A1
The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables X, Y, Q1, Q2 have the following meanings: X is C-R3 or...  
WO/2014/043368A1
Disclosed are methods for enhancing learning and/or memory, enhancing memory acquisition, memory retention and recall by inducing a higher long-term potentiation in hippocampal neuronal synapsis in individuals. The methods include admini...  
WO/2014/043068A1
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and...  
WO/2014/039501A1
Bolaamphiphilic compounds are provided according to formula (I): where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering GDNF or NGF into anim...  
WO/2014/037532A1
The present invention describes methods of treating dementia comprising administering an effective daily dose of N-(2-(6-fluoro-lH-indol-3-yl)ethyl-(2,2,3,3-tetrafluoropropo xy)benzylamine to improve or augment the effect of an acetylcho...  
WO/2014/039074A3
The present invention generally relates to therapeutic compositions for the treatment of mammalian disease and related methods. It more specifically relates to compositions comprising peptides for the treatment of inflammation and method...  
WO/2014/036595A1
The present disclosure relates to quinoline compounds of formula I, compositions comprising them and methods and uses for the treatment of central nervous system disorders, such as mood disorders (eg. depression), anxiety disorders, and ...  
WO/2014/039411A1
The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may ...  
WO/2014/037412A1
The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising a...  
WO/2014/039908A1
Provided are methods and compositions for inducing cells of the inner ear (for example, cochlear and utricular hair cells) to reenter to cell cycle and to proliferate. More particularly, the invention relates to the use of agents that in...  
WO/2014/038878A2
The present invention relates to a composition for brain-neuron protection and brain-disease prevention, alleviation or treatment comprising muskrat musk as an active ingredient, and the composition has an outstanding pharmacological eff...  
WO/2014/038623A1
Provided is a therapeutic agent for diseases associated with central nervous system (CNS) and/or peripheral nervous system (PNS) cholinergicity, diseases associated with smooth muscle contraction, endocrine diseases, diseases associated ...  
WO/2014/039504A1
Bolaamphiphilic compounds are provided according to formula I where HG1, HG2 and L1 are as defined herein. Provided bolaamphilphilic compounds and the pharmaceutical compositions thereof are useful for delivering biologically active drug...  
WO/2014/037881A1
The present invention pertains to the field of genomics and nanotechnology, specifically to the in vivo gene expression technologies and their application in gene therapy. It consists of the performance of the NTS-polyplex nanocomplex, w...  
WO/2014/037832A3
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enatitiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount...  
WO/2014/037834A3
The compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof are disclosed. The pharmaceutical compositions comprising an effective amo...  
WO/2014/039434A1
The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6 and R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising t...  
WO/2014/040076A1
The present disclosure is directed to a method of treating neurological disorder comprising peripheral administration to a patient in need thereof a DN-TNF polypeptide that inhibits the activity of soluble TNF- but not transmembrane TNF-α.  
WO/2014/038878A3
The present invention relates to a composition for brain-neuron protection and brain-disease prevention, alleviation or treatment comprising muskrat musk as an active ingredient, and the composition has an outstanding pharmacological eff...  
WO/2014/039138A1
The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acy...  
WO/2014/035860A1
The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β- secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in...  
WO/2014/034756A1
The present invention relates to the provision of a pharmaceutical composition for use in the treatment of status epilepticus or a method for treating status epilepticus. The present invention provides a pharmaceutical composition for us...  
WO/2014/034719A1
A compound represented by general formula (1), a salt of the compound, or a solvate of the compound or the salt, which can inhibit TLR3, 7 and/or 9 and has an excellent prophylactic and/or therapeutic effect on autoimmune diseases, infla...  
WO/2014/034898A1
The main purpose of the invention is to provide a novel pyridine derivative or a pharmaceutically acceptable salt thereof. Examples of the invention include a pyridine derivative represented by general formula [1], and a pharmaceutically...  
WO/2014/032187A1
The invention provides compounds of Formula (I) for inhibiting gh cosidases, prodrugs of the compounds, and pharmaceutical compositions comprising the compounds or prodrugs of the compounds. The invention also provides method of treating...  

Matches 701 - 750 out of 97,116